<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02363946</url>
  </required_header>
  <id_info>
    <org_study_id>ARCAAT-1001</org_study_id>
    <secondary_id>U1111-1171-0247</secondary_id>
    <secondary_id>2015-001147-36</secondary_id>
    <nct_id>NCT02363946</nct_id>
  </id_info>
  <brief_title>A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 1 Study to Determine the Safety, Tolerability, Pharmacokinetics and Effect of Circulating Alpha-1 Antitrypsin Levels of ARC-AAT in Healthy Volunteer Subjects and in Patients With Alpha-1 Antitrypsin Deficiency (AATD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arrowhead Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arrowhead Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the safety and tolerability of escalating doses of
      ARC-AAT and to evaluate the pharmacokinetics of ARC-AAT and the effect of ARC-AAT on
      circulating levels of alpha-1 antitrypsin (AAT). The study will consist of two parts, Part A
      (conducted in healthy volunteers) and Part B (conducted in AATD patients) at up to 9
      escalating dose levels with 6 participants per dose level.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy volunteers and AATD patients will be randomized to receive a single intravenous
      injection of either ARC-AAT or Placebo in double-blind fashion. Up to thirteen cohorts (6
      participants per cohort) will be enrolled. Participants in all cohorts will be confined to
      the clinical facility beginning on Day -1 with discharge on Day 2. Escalation to the next
      dose level will proceed until a participant experiences a dose-limiting toxicity (DLT) or
      there is achievement of pre-determined threshold reductions in AAT levels. Dosing in
      participants with AATD will commence based on pre-determined threshold reductions in AAT
      levels for healthy volunteers. For each participant, the duration of the study clinic visits
      is up to 11 weeks, from Screening to the End-of-Study examination. However, including a Day
      90 Follow-Up telephone call, the maximum study duration is approximately 20 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company decision to terminate the trial
  </why_stopped>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), or Discontinuations Due to TEAEs</measure>
    <time_frame>From the first dose of study treatment through Day 29 ± 1 day</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence which does not necessarily have to have a causal relationship with this treatment. TEAEs are defined as defined as AEs with onset after administration of the study drug, or when a preexisting medical condition increases in severity or frequency after study drug administration. SAEs are defined as is an AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a medically important event or reaction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Treatment-Emergent Abnormalities in Laboratory Values</measure>
    <time_frame>Day 1 through Day 29 ± 1 day</time_frame>
    <description>Laboratory values collected include: hematology (haemoglobin, lymphocytes, neutrophils, platelets, white cell count, monocytes); biochemistry (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, bilirubin, creatine kinase, creatinine, gamma-glutamyltransferase, fasting glucose, troponin I); coagulation parameters (fibrinogen, international normalized ratio); and C-reactive protein.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Treatment-Emergent Abnormalities in Vital Signs, Electrocardiograms (ECGs), Pulmonary Function, Physical Findings, and Other Observations</measure>
    <time_frame>Day 1 through Day 29 ± 1 day</time_frame>
    <description>Values collected include: vital signs (clinically concerning or symptomatic treatment emergent changes in heart rate, systolic blood pressure, diastolic blood pressure, respiratory rate, or temperature); ECGs (clinically significant changes from baseline were observed for ventricular rate, RR interval, QRS duration, QT interval or QT interval corrected for heart rate using Fridericia's formula [QTcF]; treatment emergent clinically significant changes in ST segments, P wave or T wave morphology; cardiac telemetry monitoring); clinically significant abnormal physical examination findings; treatment emergent sensitivity to bee venom; pulmonary function (clinically significant worsening in spirometry parameters and carbon monoxide diffusing capacity of the lung for carbon monoxide [DLCO]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ARC-AAT: Maximum Observed Plasma Concentration (Cmax) for the Analytes AD00370 and ARC-Melittin-Like Peptide (MLP; Part A)</measure>
    <time_frame>Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ARC-AAT: Time to Maximum Observed Concentration (Tmax) for the Analytes AD00370 and ARC-MLP (Part A)</measure>
    <time_frame>Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ARC-AAT: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Time 24 Hours (AUC0-24) for the Analytes AD00370 and ARC-MLP (Part A)</measure>
    <time_frame>Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ARC-AAT: Area Under the Plasma Concentration Versus Time Curve From From Zero to Infinity (AUCinf) for the Analytes AD00370 and ARC-MLP (Part A)</measure>
    <time_frame>Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ARC-AAT: Terminal Elimination Rate Constant Obtained From the Slope of the Line (Kel) for the Analytes AD00370 and ARC-MLP (Part A)</measure>
    <time_frame>Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ARC-AAT: Half-Life (t1/2) for the Analytes AD00370 and ARC-MLP (Part A)</measure>
    <time_frame>Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Reduction From Baseline of AAT Up to Day 29</measure>
    <time_frame>Baseline, Days 3, 8, 15, 22 and 29</time_frame>
    <description>Clinical assay for total serum AAT level was used for Part A. A quantitative measurement of AAT was used for Part B. A negative percent reduction indicates a percentage increase. Baseline AAT levels consisted of a geometric mean based on 3 assessments taken prior to study drug administration: at 2 time points during the Screening window at least 5 days apart, and on Day -1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With AAT Reduction &gt; 30% From Baseline (First Occurrence)</measure>
    <time_frame>Baseline, Days 3, 8, 15, 22 and 29</time_frame>
    <description>Data presents the study visit day upon which a participant had the first occurrence of AAT reduction of &gt; 30% from Baseline, and the number of participants who had a &gt; 30% reduction at any visit (overall). Baseline AAT levels consisted of a geometric mean based on 3 assessments taken prior to study drug administration: at 2 time points during the Screening window at least 5 days apart, and on Day -1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Percentage Reduction in Mean AAT (Nadir of Mean AAT)</measure>
    <time_frame>Study Day for Nadir of Mean AAT: Day 8 (for Part B 2 mg/kg arm), Day 15 (for Part A 0.38 mg/kg, 2 mg/kg, 4 mg/ kg, Placebo arms; Part B 4 mg/kg, Placebo arms), Day 22 (Part A 3 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg arms), Day 29 (1 mg/kg, 8 mg/kg arms)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Return From Nadir AAT Blood Levels to Above Normal or Within 15% of Baseline in &gt; 100 Days</measure>
    <time_frame>Baseline, up to Day 29, and through 100 days of follow-up</time_frame>
    <description>Baseline AAT levels consisted of a geometric mean based on 3 assessments taken prior to study drug administration: at 2 time points during the Screening window at least 5 days apart, and on Day -1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percentage Change in Circulating Blood Levels of Cytokines 2 Hours Post-Dose</measure>
    <time_frame>Pre-dose, 2 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percentage Change in Circulating Blood Levels of Complement Factors 2 Hours Post-Dose</measure>
    <time_frame>Pre-dose, 2 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Alpha-1 Antitrypsin Deficiency</condition>
  <arm_group>
    <arm_group_label>Part A: 0.38 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration of ARC-AAT intravenous (IV) injection, 0.38 mg/kg in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: 1.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: 2.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: 3.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: 4.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: 5.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: 6.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: 7.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: 8.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose administration of 0.9% normal saline IV injection in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: 2.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in participants with AATD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: 4.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in participants with AATD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: 6.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in participants with AATD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: 7.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in participants with AATD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose administration of 0.9% normal saline IV injection in participants with AATD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARC-AAT Injection</intervention_name>
    <description>RNA interference-based, liver-targeted therapeutic</description>
    <arm_group_label>Part A: 0.38 mg/kg</arm_group_label>
    <arm_group_label>Part A: 1.0 mg/kg</arm_group_label>
    <arm_group_label>Part A: 2.0 mg/kg</arm_group_label>
    <arm_group_label>Part A: 3.0 mg/kg</arm_group_label>
    <arm_group_label>Part A: 4.0 mg/kg</arm_group_label>
    <arm_group_label>Part A: 5.0 mg/kg</arm_group_label>
    <arm_group_label>Part A: 6.0 mg/kg</arm_group_label>
    <arm_group_label>Part A: 7.0 mg/kg</arm_group_label>
    <arm_group_label>Part A: 8.0 mg/kg</arm_group_label>
    <arm_group_label>Part B: 2.0 mg/kg</arm_group_label>
    <arm_group_label>Part B: 4.0 mg/kg</arm_group_label>
    <arm_group_label>Part B: 6.0 mg/kg</arm_group_label>
    <arm_group_label>Part B: 7.0 mg/kg</arm_group_label>
    <other_name>ARC-AAT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9 % normal saline</description>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_label>Part B: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.</description>
    <arm_group_label>Part A: 0.38 mg/kg</arm_group_label>
    <arm_group_label>Part A: 1.0 mg/kg</arm_group_label>
    <arm_group_label>Part A: 2.0 mg/kg</arm_group_label>
    <arm_group_label>Part A: 3.0 mg/kg</arm_group_label>
    <arm_group_label>Part A: 4.0 mg/kg</arm_group_label>
    <arm_group_label>Part A: 5.0 mg/kg</arm_group_label>
    <arm_group_label>Part A: 6.0 mg/kg</arm_group_label>
    <arm_group_label>Part A: 7.0 mg/kg</arm_group_label>
    <arm_group_label>Part A: 8.0 mg/kg</arm_group_label>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_label>Part B: 2.0 mg/kg</arm_group_label>
    <arm_group_label>Part B: 4.0 mg/kg</arm_group_label>
    <arm_group_label>Part B: 6.0 mg/kg</arm_group_label>
    <arm_group_label>Part B: 7.0 mg/kg</arm_group_label>
    <arm_group_label>Part B: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        (Part A - Healthy Volunteers)

          -  Male or female healthy volunteers 18-50 years of age

          -  Written informed consent

          -  Body mass index between 18.0 and 28.0 kg/m2

          -  12-lead electrocardiogram (ECG) at Screening and pre-dose assessment with no
             clinically significant abnormalities

          -  Non-pregnant/non-nursing females

          -  Non-smoker for at least one year with current non-smoking status confirmed by urine
             cotinine

          -  Normal lung function (or not clinically significant per investigator assessment) based
             on spirometry and diffusion capacity of lung for carbon monoxide (DLCO) according to
             American Thoracic Society (ATS) - European Respiratory Society (ERS) criteria

          -  Highly effective, double barrier contraception (both male and female partners) during
             the study and for 3 months following the dose of ARC-AAT

          -  Willing and able to comply with all study assessments and adhere to protocol schedule

          -  Suitable venous access for blood sampling

          -  No abnormal finding of clinical relevance at screening

          -  Normal AAT level

        (Part B-Patients) - As for Part A with the following exceptions:

          -  Male or female patients 18-70 years of age

          -  Confirmed diagnosis of homozygous alpha 1-protease inhibitor deficiency (PiZZ
             genotype) not receiving alpha-1 antitrypsin augmentation therapy for more than 4 weeks

          -  BMI between 18.0 and 35.0 kg/m2

          -  Non-smoker for at least three years with current non-smoking status confirmed by urine
             cotinine

        Exclusion Criteria:

        (Part A-Healthy Volunteers)

          -  Current regular smoker of cigarettes or cigars or was a regular smoker over the past 1
             year

          -  Recent (within last 6 weeks) transfusion of fresh frozen plasma, platelets, or packed
             red blood cells, or anticipated need for transfusion during study

          -  Acute signs of hepatitis/other infection within 4 weeks of screening and/or baseline

          -  Concurrent anticoagulants

          -  Use of dietary and/or herbal supplements that can interfere with liver metabolism
             within 7 days of screening

          -  Use of any drugs known to induce or inhibit hepatic drug metabolism within 14 days
             prior to study treatment

          -  Depot injection/implant of any drug other than birth control within 3 months prior to
             study treatment

          -  Diagnosis of diabetes mellitus or history of glucose intolerance

          -  History of poorly controlled autoimmune disease or any history of autoimmune hepatitis

          -  Human immunodeficiency virus (HIV) infection

          -  Seropositive for hepatitis B virus (HBV) or hepatitis C virus (HCV), and/or history of
             delta virus hepatitis

          -  Uncontrolled hypertension (blood pressure &gt; 150/100 mmHg)

          -  History of cardiac rhythm disturbances

          -  Family history of congenital long QT syndrome or unexplained sudden cardiac death

          -  Symptomatic heart failure (per New York Heart Association [NYHA] guidelines)

          -  Unstable angina, myocardial infarction, severe cardiovascular disease, transient
             ischemic attack (TIA) or cerebrovascular accident (CVA) within past 6 months

          -  History of malignancy within last 5 years except adequately treated basal cell
             carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical
             cancer.

          -  History of major surgery within 3 months of screening

          -  Regular use of alcohol within 1 month prior to screening (i.e., more than fourteen
             units of alcohol per week)

          -  Evidence of acute inflammation, sepsis or hemolysis or clinical evidence of lower
             respiratory tract infection

          -  Diagnosis of significant psychiatric disorder

          -  Use of illicit drugs (such as cocaine, phencyclidine [PCP] and crack) within 1 year
             prior to screening or positive urine drug screen

          -  History of allergy or hypersensitivity reaction to bee venom

          -  Use of an investigational agent or device within 30 days prior to dosing or current
             participation in an investigational study

          -  Clinically significant history/presence of any gastrointestinal pathology, unresolved
             gastrointestinal symptoms, liver or kidney disease

          -  Other conditions known to interfere with the absorption, distribution, metabolism, or
             excretion of drugs

          -  Any clinically significant history/presence of poorly controlled neurological,
             endocrinal, cardiovascular, pulmonary, hematological, immunologic, psychiatric,
             metabolic or other uncontrolled systemic disease

          -  Blood donation (500 mL) within 7 days prior to study treatment

          -  History of fever within 2 weeks of screening

          -  Concomitant medical/psychiatric condition or social situation that would affect
             compliance or result in additional safety risk

          -  Excessive exercise/physical activity within 3 days of screening or enrollment or
             planned during the study

          -  History of thromboembolic disease, stroke within 6 months of baseline, and/or
             concurrent anticoagulant medication(s)

        (Part B-Patients) - As for Part A with the following exceptions:

          -  History of major surgery within 2 months of Screening

          -  Forced expiratory volume at one second (FEV1) at baseline &lt; 60%

          -  AATD patients with liver elastography score &gt; 11 at Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nucleus Network Ltd</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2333ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Edgbaston</city>
        <state>Birmingham</state>
        <zip>B15 2WB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>February 2, 2015</study_first_submitted>
  <study_first_submitted_qc>February 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2015</study_first_posted>
  <results_first_submitted>October 30, 2017</results_first_submitted>
  <results_first_submitted_qc>October 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 3, 2018</results_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>alpha-1 antitrypsin</keyword>
  <keyword>AATD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This study terminated early and no participants were enrolled in the 6.0 mg/kg and 7.0 mg/kg arms planned in Part B.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A: 0.38 mg/kg</title>
          <description>Single dose administration of ARC-AAT intravenous (IV) injection, 0.38 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="P2">
          <title>Part A: 1.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="P3">
          <title>Part A: 2.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="P4">
          <title>Part A: 3.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="P5">
          <title>Part A: 4.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="P6">
          <title>Part A: 5.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="P7">
          <title>Part A: 6.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="P8">
          <title>Part A: 7.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="P9">
          <title>Part A: 8.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="P10">
          <title>Part A: Placebo</title>
          <description>Single dose administration of 0.9% normal saline IV injection in healthy volunteers</description>
        </group>
        <group group_id="P11">
          <title>Part B: 2.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in participants with alpha-1 antitrypsin deficiency (AATD)</description>
        </group>
        <group group_id="P12">
          <title>Part B: 4.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in participants with AATD</description>
        </group>
        <group group_id="P13">
          <title>Part B: Placebo</title>
          <description>Single dose administration of 0.9% normal saline IV injection in participants with AATD</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="18"/>
                <participants group_id="P11" count="4"/>
                <participants group_id="P12" count="3"/>
                <participants group_id="P13" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="18"/>
                <participants group_id="P11" count="4"/>
                <participants group_id="P12" count="3"/>
                <participants group_id="P13" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part A: 0.38 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 0.38 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="B2">
          <title>Part A: 1.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="B3">
          <title>Part A: 2.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="B4">
          <title>Part A: 3.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="B5">
          <title>Part A: 4.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="B6">
          <title>Part A: 5.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="B7">
          <title>Part A: 6.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="B8">
          <title>Part A: 7.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="B9">
          <title>Part A: 8.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="B10">
          <title>Part A: Placebo</title>
          <description>Single dose administration of 0.9% normal saline IV injection in healthy volunteers</description>
        </group>
        <group group_id="B11">
          <title>Part B: 2.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in participants with alpha-1 antitrypsin deficiency (AATD)</description>
        </group>
        <group group_id="B12">
          <title>Part B: 4.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in participants with AATD</description>
        </group>
        <group group_id="B13">
          <title>Part B: Placebo</title>
          <description>Single dose administration of 0.9% normal saline IV injection in participants with AATD</description>
        </group>
        <group group_id="B14">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="4"/>
            <count group_id="B6" value="4"/>
            <count group_id="B7" value="4"/>
            <count group_id="B8" value="4"/>
            <count group_id="B9" value="4"/>
            <count group_id="B10" value="18"/>
            <count group_id="B11" value="4"/>
            <count group_id="B12" value="3"/>
            <count group_id="B13" value="4"/>
            <count group_id="B14" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.0" spread="9.8"/>
                    <measurement group_id="B2" value="25.0" spread="4.5"/>
                    <measurement group_id="B3" value="30.0" spread="7.8"/>
                    <measurement group_id="B4" value="29.5" spread="10.7"/>
                    <measurement group_id="B5" value="32.3" spread="5.6"/>
                    <measurement group_id="B6" value="23.8" spread="4.1"/>
                    <measurement group_id="B7" value="32.5" spread="15.3"/>
                    <measurement group_id="B8" value="26.0" spread="5.0"/>
                    <measurement group_id="B9" value="25.0" spread="1.8"/>
                    <measurement group_id="B10" value="25.4" spread="4.8"/>
                    <measurement group_id="B11" value="59.0" spread="1.8"/>
                    <measurement group_id="B12" value="64.3" spread="3.8"/>
                    <measurement group_id="B13" value="58.8" spread="9.0"/>
                    <measurement group_id="B14" value="33.4" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="12"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), or Discontinuations Due to TEAEs</title>
        <description>An adverse event (AE) is defined as any untoward medical occurrence which does not necessarily have to have a causal relationship with this treatment. TEAEs are defined as defined as AEs with onset after administration of the study drug, or when a preexisting medical condition increases in severity or frequency after study drug administration. SAEs are defined as is an AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a medically important event or reaction.</description>
        <time_frame>From the first dose of study treatment through Day 29 ± 1 day</time_frame>
        <population>All participants receiving at least 1 dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: 0.38 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 0.38 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>Part A: 1.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>Part A: 2.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>Part A: 3.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>Part A: 4.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O6">
            <title>Part A: 5.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O7">
            <title>Part A: 6.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O8">
            <title>Part A: 7.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O9">
            <title>Part A: 8.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O10">
            <title>Part A: Placebo</title>
            <description>Single dose administration of 0.9% normal saline IV injection in healthy volunteers</description>
          </group>
          <group group_id="O11">
            <title>Part B: 2.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in participants with AATD</description>
          </group>
          <group group_id="O12">
            <title>Part B: 4.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in participants with AATD</description>
          </group>
          <group group_id="O13">
            <title>Part B: Placebo</title>
            <description>Single dose administration of 0.9% normal saline IV injection in participants with AATD</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), or Discontinuations Due to TEAEs</title>
          <description>An adverse event (AE) is defined as any untoward medical occurrence which does not necessarily have to have a causal relationship with this treatment. TEAEs are defined as defined as AEs with onset after administration of the study drug, or when a preexisting medical condition increases in severity or frequency after study drug administration. SAEs are defined as is an AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a medically important event or reaction.</description>
          <population>All participants receiving at least 1 dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="18"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="9"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Drug Related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild or Moderate TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="8"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Drug Related Moderate TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Drug Related Severe TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuations Due to TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Treatment-Emergent Abnormalities in Laboratory Values</title>
        <description>Laboratory values collected include: hematology (haemoglobin, lymphocytes, neutrophils, platelets, white cell count, monocytes); biochemistry (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, bilirubin, creatine kinase, creatinine, gamma-glutamyltransferase, fasting glucose, troponin I); coagulation parameters (fibrinogen, international normalized ratio); and C-reactive protein.</description>
        <time_frame>Day 1 through Day 29 ± 1 day</time_frame>
        <population>All participants receiving at least 1 dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: 0.38 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 0.38 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>Part A: 1.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>Part A: 2.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>Part A: 3.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>Part A: 4.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O6">
            <title>Part A: 5.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O7">
            <title>Part A: 6.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O8">
            <title>Part A: 7.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O9">
            <title>Part A: 8.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O10">
            <title>Part A: Placebo</title>
            <description>Single dose administration of 0.9% normal saline IV injection in healthy volunteers</description>
          </group>
          <group group_id="O11">
            <title>Part B: 2.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in participants with AATD</description>
          </group>
          <group group_id="O12">
            <title>Part B: 4.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in participants with AATD</description>
          </group>
          <group group_id="O13">
            <title>Part B: Placebo</title>
            <description>Single dose administration of 0.9% normal saline IV injection in participants with AATD</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Treatment-Emergent Abnormalities in Laboratory Values</title>
          <description>Laboratory values collected include: hematology (haemoglobin, lymphocytes, neutrophils, platelets, white cell count, monocytes); biochemistry (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, bilirubin, creatine kinase, creatinine, gamma-glutamyltransferase, fasting glucose, troponin I); coagulation parameters (fibrinogen, international normalized ratio); and C-reactive protein.</description>
          <population>All participants receiving at least 1 dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="18"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Troponin I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Cell Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Cell Distribution Width</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Treatment-Emergent Abnormalities in Vital Signs, Electrocardiograms (ECGs), Pulmonary Function, Physical Findings, and Other Observations</title>
        <description>Values collected include: vital signs (clinically concerning or symptomatic treatment emergent changes in heart rate, systolic blood pressure, diastolic blood pressure, respiratory rate, or temperature); ECGs (clinically significant changes from baseline were observed for ventricular rate, RR interval, QRS duration, QT interval or QT interval corrected for heart rate using Fridericia's formula [QTcF]; treatment emergent clinically significant changes in ST segments, P wave or T wave morphology; cardiac telemetry monitoring); clinically significant abnormal physical examination findings; treatment emergent sensitivity to bee venom; pulmonary function (clinically significant worsening in spirometry parameters and carbon monoxide diffusing capacity of the lung for carbon monoxide [DLCO]).</description>
        <time_frame>Day 1 through Day 29 ± 1 day</time_frame>
        <population>All participants receiving at least 1 dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: 0.38 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 0.38 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>Part A: 1.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>Part A: 2.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>Part A: 3.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>Part A: 4.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O6">
            <title>Part A: 5.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O7">
            <title>Part A: 6.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O8">
            <title>Part A: 7.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O9">
            <title>Part A: 8.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O10">
            <title>Part A: Placebo</title>
            <description>Single dose administration of 0.9% normal saline IV injection in healthy volunteers</description>
          </group>
          <group group_id="O11">
            <title>Part B: 2.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in participants with AATD</description>
          </group>
          <group group_id="O12">
            <title>Part B: 4.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in participants with AATD</description>
          </group>
          <group group_id="O13">
            <title>Part B: Placebo</title>
            <description>Single dose administration of 0.9% normal saline IV injection in participants with AATD</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Treatment-Emergent Abnormalities in Vital Signs, Electrocardiograms (ECGs), Pulmonary Function, Physical Findings, and Other Observations</title>
          <description>Values collected include: vital signs (clinically concerning or symptomatic treatment emergent changes in heart rate, systolic blood pressure, diastolic blood pressure, respiratory rate, or temperature); ECGs (clinically significant changes from baseline were observed for ventricular rate, RR interval, QRS duration, QT interval or QT interval corrected for heart rate using Fridericia's formula [QTcF]; treatment emergent clinically significant changes in ST segments, P wave or T wave morphology; cardiac telemetry monitoring); clinically significant abnormal physical examination findings; treatment emergent sensitivity to bee venom; pulmonary function (clinically significant worsening in spirometry parameters and carbon monoxide diffusing capacity of the lung for carbon monoxide [DLCO]).</description>
          <population>All participants receiving at least 1 dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="18"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vital Signs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECGs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Examination Findings</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bee Venom Sensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics of ARC-AAT: Maximum Observed Plasma Concentration (Cmax) for the Analytes AD00370 and ARC-Melittin-Like Peptide (MLP; Part A)</title>
        <time_frame>Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose</time_frame>
        <population>Per protocol pharmacokinetic analysis set: all participants with evaluable concentration time profiles for each dose level who had no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: 0.38 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 0.38 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>Part A: 1.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>Part A: 2.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>Part A: 3.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>Part A: 4.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O6">
            <title>Part A: 5.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O7">
            <title>Part A: 6.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O8">
            <title>Part A: 7.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O9">
            <title>Part A: 8.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of ARC-AAT: Maximum Observed Plasma Concentration (Cmax) for the Analytes AD00370 and ARC-Melittin-Like Peptide (MLP; Part A)</title>
          <population>Per protocol pharmacokinetic analysis set: all participants with evaluable concentration time profiles for each dose level who had no major protocol violations</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Analyte AD00370</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4430" spread="1175"/>
                    <measurement group_id="O2" value="15500" spread="2811"/>
                    <measurement group_id="O3" value="32400" spread="7005"/>
                    <measurement group_id="O4" value="50650" spread="7461"/>
                    <measurement group_id="O5" value="75625" spread="8152"/>
                    <measurement group_id="O6" value="93275" spread="6133"/>
                    <measurement group_id="O7" value="115750" spread="11871"/>
                    <measurement group_id="O8" value="130250" spread="14127"/>
                    <measurement group_id="O9" value="167000" spread="7810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analyte ARC-MLP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2760" spread="508"/>
                    <measurement group_id="O2" value="9350" spread="2368"/>
                    <measurement group_id="O3" value="20700" spread="3334"/>
                    <measurement group_id="O4" value="27050" spread="5390"/>
                    <measurement group_id="O5" value="43425" spread="3872"/>
                    <measurement group_id="O6" value="48975" spread="5590"/>
                    <measurement group_id="O7" value="70050" spread="6946"/>
                    <measurement group_id="O8" value="62525" spread="4029"/>
                    <measurement group_id="O9" value="84733" spread="2875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Dose-Proportionality of Pharmacokinetic Parameter Cmax for Analyte AD00370</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>alpha estimate</param_type>
            <param_value>9.557</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Estimation of model: Parameter = alpha * Dose^beta. Determined from linear regression model: Log(Parameter) = log(Dose)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Dose-Proportionality of Pharmacokinetic Parameter Cmax for Analyte AD00370</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>beta estimate</param_type>
            <param_value>1.173</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.128</ci_lower_limit>
            <ci_upper_limit>1.218</ci_upper_limit>
            <estimate_desc>Estimation of model: Parameter = alpha * Dose^beta. Determined from linear regression model: Log(Parameter) = log(Dose)</estimate_desc>
            <other_analysis_desc>R-square (r^2)=0.98</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Dose-Proportionality of Pharmacokinetic Parameter Cmax for Analyte ARC-MLP</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>alpha estimate</param_type>
            <param_value>9.824</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.030</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Estimation of model: Parameter = alpha * Dose^beta. Determined from linear regression model: Log(Parameter) = log(Dose)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Dose-Proportionality of Pharmacokinetic Parameter Cmax for Analyte ARC-MLP</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>beta estimate</param_type>
            <param_value>1.103</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.029</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.054</ci_lower_limit>
            <ci_upper_limit>1.153</ci_upper_limit>
            <estimate_desc>Estimation of model: Parameter = alpha * Dose^beta. Determined from linear regression model: Log(Parameter) = log(Dose)</estimate_desc>
            <other_analysis_desc>R-square (r^2)=0.98</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics of ARC-AAT: Time to Maximum Observed Concentration (Tmax) for the Analytes AD00370 and ARC-MLP (Part A)</title>
        <time_frame>Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose</time_frame>
        <population>Per protocol pharmacokinetic analysis set: all participants with evaluable concentration time profiles for each dose level who had no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: 0.38 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 0.38 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>Part A: 1.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>Part A: 2.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>Part A: 3.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>Part A: 4.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O6">
            <title>Part A: 5.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O7">
            <title>Part A: 6.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O8">
            <title>Part A: 7.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O9">
            <title>Part A: 8.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of ARC-AAT: Time to Maximum Observed Concentration (Tmax) for the Analytes AD00370 and ARC-MLP (Part A)</title>
          <population>Per protocol pharmacokinetic analysis set: all participants with evaluable concentration time profiles for each dose level who had no major protocol violations</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Analyte AD00370</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.083" lower_limit="0.083" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.083" lower_limit="0.083" upper_limit="0.083"/>
                    <measurement group_id="O3" value="0.083" lower_limit="0.083" upper_limit="0.083"/>
                    <measurement group_id="O4" value="0.083" lower_limit="0.083" upper_limit="0.50"/>
                    <measurement group_id="O5" value="0.083" lower_limit="0.083" upper_limit="0.083"/>
                    <measurement group_id="O6" value="0.083" lower_limit="0.083" upper_limit="0.50"/>
                    <measurement group_id="O7" value="0.083" lower_limit="0.083" upper_limit="0.50"/>
                    <measurement group_id="O8" value="0.083" lower_limit="0.083" upper_limit="0.50"/>
                    <measurement group_id="O9" value="0.50" lower_limit="0.083" upper_limit="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analyte ARC-MLP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.083" lower_limit="0.083" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.083" lower_limit="0.083" upper_limit="0.083"/>
                    <measurement group_id="O3" value="0.083" lower_limit="0.083" upper_limit="0.083"/>
                    <measurement group_id="O4" value="0.083" lower_limit="0.083" upper_limit="0.083"/>
                    <measurement group_id="O5" value="0.083" lower_limit="0.083" upper_limit="0.50"/>
                    <measurement group_id="O6" value="0.083" lower_limit="0.083" upper_limit="0.50"/>
                    <measurement group_id="O7" value="0.083" lower_limit="0.083" upper_limit="1.00"/>
                    <measurement group_id="O8" value="0.50" lower_limit="0.083" upper_limit="1.00"/>
                    <measurement group_id="O9" value="0.50" lower_limit="0.50" upper_limit="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics of ARC-AAT: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Time 24 Hours (AUC0-24) for the Analytes AD00370 and ARC-MLP (Part A)</title>
        <time_frame>Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose</time_frame>
        <population>Per protocol pharmacokinetic analysis set: all participants with evaluable concentration time profiles for each dose level who had no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: 0.38 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 0.38 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>Part A: 1.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>Part A: 2.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>Part A: 3.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>Part A: 4.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O6">
            <title>Part A: 5.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O7">
            <title>Part A: 6.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O8">
            <title>Part A: 7.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O9">
            <title>Part A: 8.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of ARC-AAT: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Time 24 Hours (AUC0-24) for the Analytes AD00370 and ARC-MLP (Part A)</title>
          <population>Per protocol pharmacokinetic analysis set: all participants with evaluable concentration time profiles for each dose level who had no major protocol violations</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Analyte AD00370</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26905" spread="10793"/>
                    <measurement group_id="O2" value="85138" spread="12234"/>
                    <measurement group_id="O3" value="162198" spread="56129"/>
                    <measurement group_id="O4" value="282710" spread="61810"/>
                    <measurement group_id="O5" value="438532" spread="38111"/>
                    <measurement group_id="O6" value="541628" spread="49787"/>
                    <measurement group_id="O7" value="708648" spread="212442"/>
                    <measurement group_id="O8" value="763392" spread="96095"/>
                    <measurement group_id="O9" value="908117" spread="144892"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analyte ARC-MLP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28734" spread="6757"/>
                    <measurement group_id="O2" value="82627" spread="32332"/>
                    <measurement group_id="O3" value="213250" spread="67886"/>
                    <measurement group_id="O4" value="291876" spread="58240"/>
                    <measurement group_id="O5" value="458790" spread="48790"/>
                    <measurement group_id="O6" value="459939" spread="81820"/>
                    <measurement group_id="O7" value="699833" spread="85172"/>
                    <measurement group_id="O8" value="716938" spread="46783"/>
                    <measurement group_id="O9" value="1011569" spread="101693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Dose-Proportionality of Pharmacokinetic Parameter AUC0-24 for Analyte AD00370</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>alpha estimate</param_type>
            <param_value>11.274</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.057</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Estimation of model: Parameter = alpha * Dose^beta. Determined from linear regression model: Log(Parameter) = log(Dose)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Dose-Proportionality of Pharmacokinetic Parameter AUC0-24 for Analyte AD00370</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>beta estimate</param_type>
            <param_value>1.181</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.112</ci_lower_limit>
            <ci_upper_limit>1.249</ci_upper_limit>
            <estimate_desc>Estimation of model: Parameter = alpha * Dose^beta. Determined from linear regression model: Log(Parameter) = log(Dose)</estimate_desc>
            <other_analysis_desc>R-square (r^2)=0.96</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Dose-Proportionality of Pharmacokinetic Parameter AUC0-24 for Analyte ARC-MLP</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>alpha estimate</param_type>
            <param_value>12.133</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Estimation of model: Parameter = alpha * Dose^beta. Determined from linear regression model: Log(Parameter) = log(Dose)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Dose-Proportionality of Pharmacokinetic Parameter AUC0-24 for Analyte ARC-MLP</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>beta estimate</param_type>
            <param_value>1.147</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.080</ci_lower_limit>
            <ci_upper_limit>1.215</ci_upper_limit>
            <estimate_desc>Estimation of model: Parameter = alpha * Dose^beta. Determined from linear regression model: Log(Parameter) = log(Dose)</estimate_desc>
            <other_analysis_desc>R-square (r^2)=0.96</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics of ARC-AAT: Area Under the Plasma Concentration Versus Time Curve From From Zero to Infinity (AUCinf) for the Analytes AD00370 and ARC-MLP (Part A)</title>
        <time_frame>Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose</time_frame>
        <population>Per protocol pharmacokinetic analysis set: all participants with evaluable concentration time profiles for each dose level who had no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: 0.38 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 0.38 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>Part A: 1.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>Part A: 2.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>Part A: 3.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>Part A: 4.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O6">
            <title>Part A: 5.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O7">
            <title>Part A: 6.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O8">
            <title>Part A: 7.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O9">
            <title>Part A: 8.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of ARC-AAT: Area Under the Plasma Concentration Versus Time Curve From From Zero to Infinity (AUCinf) for the Analytes AD00370 and ARC-MLP (Part A)</title>
          <population>Per protocol pharmacokinetic analysis set: all participants with evaluable concentration time profiles for each dose level who had no major protocol violations</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Analyte AD00370</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27388" spread="11183"/>
                    <measurement group_id="O2" value="85906" spread="12529"/>
                    <measurement group_id="O3" value="164856" spread="58070"/>
                    <measurement group_id="O4" value="285487" spread="62310"/>
                    <measurement group_id="O5" value="441239" spread="39032"/>
                    <measurement group_id="O6" value="547045" spread="52126"/>
                    <measurement group_id="O7" value="719843" spread="226599"/>
                    <measurement group_id="O8" value="771924" spread="100469"/>
                    <measurement group_id="O9" value="916343" spread="147924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analyte ARC-MLP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34718" spread="8345"/>
                    <measurement group_id="O2" value="103116" spread="48837"/>
                    <measurement group_id="O3" value="277684" spread="119873"/>
                    <measurement group_id="O4" value="380506" spread="89117"/>
                    <measurement group_id="O5" value="559372" spread="82769"/>
                    <measurement group_id="O6" value="569056" spread="129569"/>
                    <measurement group_id="O7" value="872798" spread="136277"/>
                    <measurement group_id="O8" value="952668" spread="99324"/>
                    <measurement group_id="O9" value="1251318" spread="138571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Dose-Proportionality of Pharmacokinetic Parameter AUCinf for Analyte AD00370</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>alpha estimate</param_type>
            <param_value>11.286</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.058</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Estimation of model: Parameter = alpha * Dose^beta. Determined from linear regression model: Log(Parameter) = log(Dose)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Dose-Proportionality of Pharmacokinetic Parameter AUCinf for Analyte AD00370</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>beta estimate</param_type>
            <param_value>1.179</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.110</ci_lower_limit>
            <ci_upper_limit>1.249</ci_upper_limit>
            <estimate_desc>Estimation of model: Parameter = alpha * Dose^beta. Determined from linear regression model: Log(Parameter) = log(Dose)</estimate_desc>
            <other_analysis_desc>R-square (r^2)=0.96</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Dose-Proportionality of Pharmacokinetic Parameter AUCinf for Analyte ARC-MLP</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>alpha estimate</param_type>
            <param_value>12.347</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.049</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Estimation of model: Parameter = alpha * Dose^beta. Determined from linear regression model: Log(Parameter) = log(Dose)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Dose-Proportionality of Pharmacokinetic Parameter AUCinf for Analyte ARC-MLP</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>beta estimate</param_type>
            <param_value>1.163</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.049</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.081</ci_lower_limit>
            <ci_upper_limit>1.245</ci_upper_limit>
            <estimate_desc>Estimation of model: Parameter = alpha * Dose^beta. Determined from linear regression model: Log(Parameter) = log(Dose)</estimate_desc>
            <other_analysis_desc>R-square (r^2)=0.95</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics of ARC-AAT: Terminal Elimination Rate Constant Obtained From the Slope of the Line (Kel) for the Analytes AD00370 and ARC-MLP (Part A)</title>
        <time_frame>Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose</time_frame>
        <population>Per protocol pharmacokinetic analysis set: all participants with evaluable concentration time profiles for each dose level who had no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: 0.38 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 0.38 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>Part A: 1.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>Part A: 2.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>Part A: 3.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>Part A: 4.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O6">
            <title>Part A: 5.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O7">
            <title>Part A: 6.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O8">
            <title>Part A: 7.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O9">
            <title>Part A: 8.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of ARC-AAT: Terminal Elimination Rate Constant Obtained From the Slope of the Line (Kel) for the Analytes AD00370 and ARC-MLP (Part A)</title>
          <population>Per protocol pharmacokinetic analysis set: all participants with evaluable concentration time profiles for each dose level who had no major protocol violations</population>
          <units>1/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Analyte AD00370</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.186" spread="0.050"/>
                    <measurement group_id="O2" value="0.177" spread="0.004"/>
                    <measurement group_id="O3" value="0.170" spread="0.013"/>
                    <measurement group_id="O4" value="0.174" spread="0.004"/>
                    <measurement group_id="O5" value="0.185" spread="0.011"/>
                    <measurement group_id="O6" value="0.183" spread="0.006"/>
                    <measurement group_id="O7" value="0.185" spread="0.023"/>
                    <measurement group_id="O8" value="0.178" spread="0.010"/>
                    <measurement group_id="O9" value="0.181" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analyte ARC-MLP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0786" spread="0.0141"/>
                    <measurement group_id="O2" value="0.0879" spread="0.0297"/>
                    <measurement group_id="O3" value="0.0778" spread="0.0265"/>
                    <measurement group_id="O4" value="0.0762" spread="0.0218"/>
                    <measurement group_id="O5" value="0.0846" spread="0.0158"/>
                    <measurement group_id="O6" value="0.0815" spread="0.0231"/>
                    <measurement group_id="O7" value="0.0768" spread="0.0104"/>
                    <measurement group_id="O8" value="0.0622" spread="0.0077"/>
                    <measurement group_id="O9" value="0.0730" spread="0.0046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics of ARC-AAT: Half-Life (t1/2) for the Analytes AD00370 and ARC-MLP (Part A)</title>
        <time_frame>Day 1, 2, and 3 at pre-dose and then at 0.08, 0.5, 1, 3, 6, 24 and 48 hours post-dose</time_frame>
        <population>Per protocol pharmacokinetic analysis set: all participants with evaluable concentration time profiles for each dose level who had no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: 0.38 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 0.38 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>Part A: 1.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>Part A: 2.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>Part A: 3.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>Part A: 4.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O6">
            <title>Part A: 5.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O7">
            <title>Part A: 6.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O8">
            <title>Part A: 7.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O9">
            <title>Part A: 8.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of ARC-AAT: Half-Life (t1/2) for the Analytes AD00370 and ARC-MLP (Part A)</title>
          <population>Per protocol pharmacokinetic analysis set: all participants with evaluable concentration time profiles for each dose level who had no major protocol violations</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Analyte AD00370</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.90" spread="0.84"/>
                    <measurement group_id="O2" value="3.91" spread="0.09"/>
                    <measurement group_id="O3" value="4.09" spread="0.31"/>
                    <measurement group_id="O4" value="3.99" spread="0.09"/>
                    <measurement group_id="O5" value="3.75" spread="0.22"/>
                    <measurement group_id="O6" value="3.78" spread="0.12"/>
                    <measurement group_id="O7" value="3.80" spread="0.53"/>
                    <measurement group_id="O8" value="3.90" spread="0.23"/>
                    <measurement group_id="O9" value="3.83" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analyte ARC-MLP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.02" spread="1.50"/>
                    <measurement group_id="O2" value="8.60" spread="2.88"/>
                    <measurement group_id="O3" value="9.77" spread="3.39"/>
                    <measurement group_id="O4" value="9.83" spread="3.46"/>
                    <measurement group_id="O5" value="8.43" spread="1.68"/>
                    <measurement group_id="O6" value="8.93" spread="1.98"/>
                    <measurement group_id="O7" value="9.17" spread="1.40"/>
                    <measurement group_id="O8" value="11.3" spread="1.5"/>
                    <measurement group_id="O9" value="9.52" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Reduction From Baseline of AAT Up to Day 29</title>
        <description>Clinical assay for total serum AAT level was used for Part A. A quantitative measurement of AAT was used for Part B. A negative percent reduction indicates a percentage increase. Baseline AAT levels consisted of a geometric mean based on 3 assessments taken prior to study drug administration: at 2 time points during the Screening window at least 5 days apart, and on Day -1.</description>
        <time_frame>Baseline, Days 3, 8, 15, 22 and 29</time_frame>
        <population>All participants who received a full dose of study drug with evaluable data at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: 0.38 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 0.38 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>Part A: 1.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>Part A: 2.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>Part A: 3.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>Part A: 4.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O6">
            <title>Part A: 5.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O7">
            <title>Part A: 6.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O8">
            <title>Part A: 7.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O9">
            <title>Part A: 8.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O10">
            <title>Part A: Placebo</title>
            <description>Single dose administration of 0.9% normal saline IV injection in healthy volunteers</description>
          </group>
          <group group_id="O11">
            <title>Part B: 2.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in participants with AATD</description>
          </group>
          <group group_id="O12">
            <title>Part B: 4.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in participants with AATD</description>
          </group>
          <group group_id="O13">
            <title>Part B: Placebo</title>
            <description>Single dose administration of 0.9% normal saline IV injection in participants with AATD</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Reduction From Baseline of AAT Up to Day 29</title>
          <description>Clinical assay for total serum AAT level was used for Part A. A quantitative measurement of AAT was used for Part B. A negative percent reduction indicates a percentage increase. Baseline AAT levels consisted of a geometric mean based on 3 assessments taken prior to study drug administration: at 2 time points during the Screening window at least 5 days apart, and on Day -1.</description>
          <population>All participants who received a full dose of study drug with evaluable data at given time point.</population>
          <units>percentage reduction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="18"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="18"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="3"/>
                    <count group_id="O13" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.70" spread="8.45"/>
                    <measurement group_id="O2" value="-7.00" spread="3.19"/>
                    <measurement group_id="O3" value="-1.94" spread="4.49"/>
                    <measurement group_id="O4" value="13.76" spread="4.74"/>
                    <measurement group_id="O5" value="20.76" spread="5.86"/>
                    <measurement group_id="O6" value="21.65" spread="5.28"/>
                    <measurement group_id="O7" value="22.20" spread="8.80"/>
                    <measurement group_id="O8" value="20.35" spread="11.83"/>
                    <measurement group_id="O9" value="30.07" spread="6.37"/>
                    <measurement group_id="O10" value="-4.65" spread="11.13"/>
                    <measurement group_id="O11" value="11.5" spread="11.5"/>
                    <measurement group_id="O12" value="43.8" spread="5.6"/>
                    <measurement group_id="O13" value="-13.0" spread="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="18"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="3"/>
                    <count group_id="O13" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="2.86"/>
                    <measurement group_id="O2" value="10.90" spread="8.30"/>
                    <measurement group_id="O3" value="13.40" spread="11.68"/>
                    <measurement group_id="O4" value="33.20" spread="14.33"/>
                    <measurement group_id="O5" value="46.92" spread="6.16"/>
                    <measurement group_id="O6" value="58.52" spread="6.15"/>
                    <measurement group_id="O7" value="58.44" spread="7.50"/>
                    <measurement group_id="O8" value="50.95" spread="6.82"/>
                    <measurement group_id="O9" value="58.66" spread="2.99"/>
                    <measurement group_id="O10" value="-0.26" spread="10.80"/>
                    <measurement group_id="O11" value="43.1" spread="26.7"/>
                    <measurement group_id="O12" value="54.4" spread="22.2"/>
                    <measurement group_id="O13" value="7.0" spread="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="17"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="3"/>
                    <count group_id="O13" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" spread="2.62"/>
                    <measurement group_id="O2" value="3.89" spread="2.78"/>
                    <measurement group_id="O3" value="26.72" spread="14.31"/>
                    <measurement group_id="O4" value="33.65" spread="14.66"/>
                    <measurement group_id="O5" value="61.53" spread="11.75"/>
                    <measurement group_id="O6" value="74.20" spread="7.03"/>
                    <measurement group_id="O7" value="75.75" spread="5.95"/>
                    <measurement group_id="O8" value="73.57" spread="2.76"/>
                    <measurement group_id="O9" value="79.18" spread="4.03"/>
                    <measurement group_id="O10" value="0.78" spread="11.91"/>
                    <measurement group_id="O11" value="37.5" spread="20.4"/>
                    <measurement group_id="O12" value="77.7" spread="1.5"/>
                    <measurement group_id="O13" value="7.2" spread="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="17"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="3"/>
                    <count group_id="O13" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="4.01"/>
                    <measurement group_id="O2" value="6.81" spread="8.81"/>
                    <measurement group_id="O3" value="15.59" spread="9.21"/>
                    <measurement group_id="O4" value="35.50" spread="15.24"/>
                    <measurement group_id="O5" value="58.64" spread="13.55"/>
                    <measurement group_id="O6" value="77.18" spread="9.94"/>
                    <measurement group_id="O7" value="83.12" spread="3.67"/>
                    <measurement group_id="O8" value="81.14" spread="1.17"/>
                    <measurement group_id="O9" value="87.47" spread="2.09"/>
                    <measurement group_id="O10" value="0.50" spread="13.48"/>
                    <measurement group_id="O11" value="25.1" spread="17.2"/>
                    <measurement group_id="O12" value="59.5" spread="13.4"/>
                    <measurement group_id="O13" value="1.7" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="18"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="3"/>
                    <count group_id="O13" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="10.37"/>
                    <measurement group_id="O2" value="25.87" spread="6.58"/>
                    <measurement group_id="O3" value="13.93" spread="17.16"/>
                    <measurement group_id="O4" value="27.40" spread="10.65"/>
                    <measurement group_id="O5" value="50.02" spread="20.46"/>
                    <measurement group_id="O6" value="73.15" spread="14.46"/>
                    <measurement group_id="O7" value="82.99" spread="4.19"/>
                    <measurement group_id="O8" value="78.20" spread="7.83"/>
                    <measurement group_id="O9" value="87.93" spread="1.75"/>
                    <measurement group_id="O10" value="-1.56" spread="8.66"/>
                    <measurement group_id="O11" value="21.0" spread="24.4"/>
                    <measurement group_id="O12" value="65.2" spread="8.7"/>
                    <measurement group_id="O13" value="-7.2" spread="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With AAT Reduction &gt; 30% From Baseline (First Occurrence)</title>
        <description>Data presents the study visit day upon which a participant had the first occurrence of AAT reduction of &gt; 30% from Baseline, and the number of participants who had a &gt; 30% reduction at any visit (overall). Baseline AAT levels consisted of a geometric mean based on 3 assessments taken prior to study drug administration: at 2 time points during the Screening window at least 5 days apart, and on Day -1.</description>
        <time_frame>Baseline, Days 3, 8, 15, 22 and 29</time_frame>
        <population>All participants who received a full dose of study drug with evaluable data at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: 0.38 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 0.38 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>Part A: 1.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>Part A: 2.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>Part A: 3.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>Part A: 4.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O6">
            <title>Part A: 5.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O7">
            <title>Part A: 6.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O8">
            <title>Part A: 7.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O9">
            <title>Part A: 8.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O10">
            <title>Part A: Placebo</title>
            <description>Single dose administration of 0.9% normal saline IV injection in healthy volunteers</description>
          </group>
          <group group_id="O11">
            <title>Part B: 2.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in participants with AATD</description>
          </group>
          <group group_id="O12">
            <title>Part B: 4.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in participants with AATD</description>
          </group>
          <group group_id="O13">
            <title>Part B: Placebo</title>
            <description>Single dose administration of 0.9% normal saline IV injection in participants with AATD</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With AAT Reduction &gt; 30% From Baseline (First Occurrence)</title>
          <description>Data presents the study visit day upon which a participant had the first occurrence of AAT reduction of &gt; 30% from Baseline, and the number of participants who had a &gt; 30% reduction at any visit (overall). Baseline AAT levels consisted of a geometric mean based on 3 assessments taken prior to study drug administration: at 2 time points during the Screening window at least 5 days apart, and on Day -1.</description>
          <population>All participants who received a full dose of study drug with evaluable data at given time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="18"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Percentage Reduction in Mean AAT (Nadir of Mean AAT)</title>
        <time_frame>Study Day for Nadir of Mean AAT: Day 8 (for Part B 2 mg/kg arm), Day 15 (for Part A 0.38 mg/kg, 2 mg/kg, 4 mg/ kg, Placebo arms; Part B 4 mg/kg, Placebo arms), Day 22 (Part A 3 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg arms), Day 29 (1 mg/kg, 8 mg/kg arms)</time_frame>
        <population>All participants who received a full dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: 0.38 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 0.38 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>Part A: 1.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>Part A: 2.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>Part A: 3.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>Part A: 4.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O6">
            <title>Part A: 5.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O7">
            <title>Part A: 6.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O8">
            <title>Part A: 7.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O9">
            <title>Part A: 8.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O10">
            <title>Part A: Placebo</title>
            <description>Single dose administration of 0.9% normal saline IV injection in healthy volunteers</description>
          </group>
          <group group_id="O11">
            <title>Part B: 2.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in participants with AATD</description>
          </group>
          <group group_id="O12">
            <title>Part B: 4.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in participants with AATD</description>
          </group>
          <group group_id="O13">
            <title>Part B: Placebo</title>
            <description>Single dose administration of 0.9% normal saline IV injection in participants with AATD</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Percentage Reduction in Mean AAT (Nadir of Mean AAT)</title>
          <population>All participants who received a full dose of study drug.</population>
          <units>percentage reduction</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="18"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="25.9"/>
                    <measurement group_id="O3" value="26.7"/>
                    <measurement group_id="O4" value="35.5"/>
                    <measurement group_id="O5" value="61.5"/>
                    <measurement group_id="O6" value="77.2"/>
                    <measurement group_id="O7" value="83.1"/>
                    <measurement group_id="O8" value="81.1"/>
                    <measurement group_id="O9" value="87.9"/>
                    <measurement group_id="O10" value="0.78"/>
                    <measurement group_id="O11" value="43.1"/>
                    <measurement group_id="O12" value="77.7"/>
                    <measurement group_id="O13" value="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Return From Nadir AAT Blood Levels to Above Normal or Within 15% of Baseline in &gt; 100 Days</title>
        <description>Baseline AAT levels consisted of a geometric mean based on 3 assessments taken prior to study drug administration: at 2 time points during the Screening window at least 5 days apart, and on Day -1.</description>
        <time_frame>Baseline, up to Day 29, and through 100 days of follow-up</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: 0.38 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 0.38 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>Part A: 1.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>Part A: 2.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>Part A: 3.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>Part A: 4.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O6">
            <title>Part A: 5.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O7">
            <title>Part A: 6.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O8">
            <title>Part A: 7.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O9">
            <title>Part A: 8.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O10">
            <title>Part A: Placebo</title>
            <description>Single dose administration of 0.9% normal saline IV injection in healthy volunteers</description>
          </group>
          <group group_id="O11">
            <title>Part B: 2.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in participants with AATD</description>
          </group>
          <group group_id="O12">
            <title>Part B: 4.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in participants with AATD</description>
          </group>
          <group group_id="O13">
            <title>Part B: Placebo</title>
            <description>Single dose administration of 0.9% normal saline IV injection in participants with AATD</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Return From Nadir AAT Blood Levels to Above Normal or Within 15% of Baseline in &gt; 100 Days</title>
          <description>Baseline AAT levels consisted of a geometric mean based on 3 assessments taken prior to study drug administration: at 2 time points during the Screening window at least 5 days apart, and on Day -1.</description>
          <population>All participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="18"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="18"/>
                    <measurement group_id="O11" value="4"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percentage Change in Circulating Blood Levels of Cytokines 2 Hours Post-Dose</title>
        <time_frame>Pre-dose, 2 hours post-dose</time_frame>
        <population>Participants with available data for given parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: 0.38 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 0.38 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>Part A: 1.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>Part A: 2.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>Part A: 3.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>Part A: 4.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O6">
            <title>Part A: 5.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O7">
            <title>Part A: 6.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O8">
            <title>Part A: 7.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O9">
            <title>Part A: 8.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O10">
            <title>Part A: Placebo</title>
            <description>Single dose administration of 0.9% normal saline IV injection in healthy volunteers</description>
          </group>
          <group group_id="O11">
            <title>Part B: 2.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in participants with AATD</description>
          </group>
          <group group_id="O12">
            <title>Part B: 4.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in participants with AATD</description>
          </group>
          <group group_id="O13">
            <title>Part B: Placebo</title>
            <description>Single dose administration of 0.9% normal saline IV injection in participants with AATD</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage Change in Circulating Blood Levels of Cytokines 2 Hours Post-Dose</title>
          <population>Participants with available data for given parameter.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="18"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="1"/>
                <count group_id="O13" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum interleukin-1 beta</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0"/>
                    <measurement group_id="O8" value="-9" spread="17"/>
                    <measurement group_id="O9" value="9" spread="18"/>
                    <measurement group_id="O10" value="0" spread="0"/>
                    <measurement group_id="O11" value="-2" spread="10"/>
                    <measurement group_id="O12" value="114" spread="NA">only 1 participant evaluated</measurement>
                    <measurement group_id="O13" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum interleukin-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="8"/>
                    <measurement group_id="O2" value="79" spread="141"/>
                    <measurement group_id="O3" value="95" spread="113"/>
                    <measurement group_id="O4" value="50" spread="64"/>
                    <measurement group_id="O5" value="277" spread="308"/>
                    <measurement group_id="O6" value="100" spread="191"/>
                    <measurement group_id="O7" value="146" spread="261"/>
                    <measurement group_id="O8" value="258" spread="285"/>
                    <measurement group_id="O9" value="364" spread="255"/>
                    <measurement group_id="O10" value="-1" spread="7"/>
                    <measurement group_id="O11" value="60" spread="52"/>
                    <measurement group_id="O12" value="130" spread="NA">only 1 participant evaluated</measurement>
                    <measurement group_id="O13" value="56" spread="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum interleukin-8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" spread="70"/>
                    <measurement group_id="O2" value="280" spread="328"/>
                    <measurement group_id="O3" value="336" spread="297"/>
                    <measurement group_id="O4" value="103" spread="101"/>
                    <measurement group_id="O5" value="1712" spread="981"/>
                    <measurement group_id="O6" value="564" spread="576"/>
                    <measurement group_id="O7" value="252" spread="363"/>
                    <measurement group_id="O8" value="695" spread="635"/>
                    <measurement group_id="O9" value="2015" spread="1569"/>
                    <measurement group_id="O10" value="-6" spread="17"/>
                    <measurement group_id="O11" value="197" spread="319"/>
                    <measurement group_id="O12" value="46" spread="NA">only 1 participant evaluated</measurement>
                    <measurement group_id="O13" value="-44" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum interleukin-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5" spread="19"/>
                    <measurement group_id="O2" value="72" spread="134"/>
                    <measurement group_id="O3" value="51" spread="52"/>
                    <measurement group_id="O4" value="42" spread="45"/>
                    <measurement group_id="O5" value="27" spread="54"/>
                    <measurement group_id="O6" value="19" spread="28"/>
                    <measurement group_id="O7" value="116" spread="160"/>
                    <measurement group_id="O8" value="377" spread="498"/>
                    <measurement group_id="O9" value="638" spread="536"/>
                    <measurement group_id="O10" value="-2" spread="7"/>
                    <measurement group_id="O11" value="0" spread="0"/>
                    <measurement group_id="O12" value="0" spread="NA">only 1 participant evaluated</measurement>
                    <measurement group_id="O13" value="-5" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum interleukin-12p40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="37"/>
                    <measurement group_id="O2" value="2" spread="5"/>
                    <measurement group_id="O3" value="5" spread="8"/>
                    <measurement group_id="O4" value="6" spread="9"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="152" spread="217"/>
                    <measurement group_id="O8" value="-9" spread="19"/>
                    <measurement group_id="O9" value="29" spread="38"/>
                    <measurement group_id="O10" value="-3" spread="10"/>
                    <measurement group_id="O11" value="-4" spread="13"/>
                    <measurement group_id="O12" value="79" spread="NA">only 1 participant evaluated</measurement>
                    <measurement group_id="O13" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum interleukin-12p70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="54" spread="108"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0"/>
                    <measurement group_id="O8" value="166" spread="389"/>
                    <measurement group_id="O9" value="82" spread="130"/>
                    <measurement group_id="O10" value="-1" spread="4"/>
                    <measurement group_id="O11" value="-3" spread="5"/>
                    <measurement group_id="O12" value="48" spread="NA">only 1 participant evaluated</measurement>
                    <measurement group_id="O13" value="23" spread="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum monocyte chemoattractant protein-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123" spread="171"/>
                    <measurement group_id="O2" value="442" spread="133"/>
                    <measurement group_id="O3" value="505" spread="254"/>
                    <measurement group_id="O4" value="632" spread="281"/>
                    <measurement group_id="O5" value="1176" spread="427"/>
                    <measurement group_id="O6" value="1297" spread="747"/>
                    <measurement group_id="O7" value="543" spread="497"/>
                    <measurement group_id="O8" value="906" spread="720"/>
                    <measurement group_id="O9" value="2014" spread="427"/>
                    <measurement group_id="O10" value="1" spread="13"/>
                    <measurement group_id="O11" value="262" spread="262"/>
                    <measurement group_id="O12" value="44" spread="NA">only 1 participant evaluated</measurement>
                    <measurement group_id="O13" value="-27" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum macrophage inflammatory protein-1 alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147" spread="126"/>
                    <measurement group_id="O2" value="294" spread="275"/>
                    <measurement group_id="O3" value="386" spread="556"/>
                    <measurement group_id="O4" value="264" spread="438"/>
                    <measurement group_id="O5" value="1674" spread="1022"/>
                    <measurement group_id="O6" value="1096" spread="578"/>
                    <measurement group_id="O7" value="406" spread="416"/>
                    <measurement group_id="O8" value="1003" spread="814"/>
                    <measurement group_id="O9" value="854" spread="538"/>
                    <measurement group_id="O10" value="15" spread="69"/>
                    <measurement group_id="O11" value="246" spread="304"/>
                    <measurement group_id="O12" value="0" spread="NA">only 1 participant evaluated</measurement>
                    <measurement group_id="O13" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum tumor necrosis factor alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66" spread="69"/>
                    <measurement group_id="O2" value="207" spread="90"/>
                    <measurement group_id="O3" value="286" spread="90"/>
                    <measurement group_id="O4" value="187" spread="156"/>
                    <measurement group_id="O5" value="818" spread="344"/>
                    <measurement group_id="O6" value="476" spread="137"/>
                    <measurement group_id="O7" value="301" spread="237"/>
                    <measurement group_id="O8" value="761" spread="492"/>
                    <measurement group_id="O9" value="742" spread="273"/>
                    <measurement group_id="O10" value="3" spread="27"/>
                    <measurement group_id="O11" value="107" spread="152"/>
                    <measurement group_id="O12" value="55" spread="NA">only 1 participant evaluated</measurement>
                    <measurement group_id="O13" value="-29" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum interferon alpha 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="4" spread="7"/>
                    <measurement group_id="O7" value="73" spread="147"/>
                    <measurement group_id="O8" value="172" spread="366"/>
                    <measurement group_id="O9" value="515" spread="529"/>
                    <measurement group_id="O10" value="5" spread="20"/>
                    <measurement group_id="O11" value="-3" spread="7"/>
                    <measurement group_id="O12" value="700" spread="NA">only 1 participant evaluated</measurement>
                    <measurement group_id="O13" value="69" spread="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percentage Change in Circulating Blood Levels of Complement Factors 2 Hours Post-Dose</title>
        <time_frame>Pre-dose, 2 hours post-dose</time_frame>
        <population>Participants with available data for given parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: 0.38 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 0.38 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>Part A: 1.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>Part A: 2.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>Part A: 3.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>Part A: 4.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O6">
            <title>Part A: 5.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O7">
            <title>Part A: 6.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O8">
            <title>Part A: 7.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O9">
            <title>Part A: 8.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers</description>
          </group>
          <group group_id="O10">
            <title>Part A: Placebo</title>
            <description>Single dose administration of 0.9% normal saline IV injection in healthy volunteers</description>
          </group>
          <group group_id="O11">
            <title>Part B: 2.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in participants with AATD</description>
          </group>
          <group group_id="O12">
            <title>Part B: 4.0 mg/kg</title>
            <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in participants with AATD</description>
          </group>
          <group group_id="O13">
            <title>Part B: Placebo</title>
            <description>Single dose administration of 0.9% normal saline IV injection in participants with AATD</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage Change in Circulating Blood Levels of Complement Factors 2 Hours Post-Dose</title>
          <population>Participants with available data for given parameter.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="18"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="1"/>
                <count group_id="O13" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma Bb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" spread="16"/>
                    <measurement group_id="O2" value="56" spread="25"/>
                    <measurement group_id="O3" value="76" spread="37"/>
                    <measurement group_id="O4" value="133" spread="29"/>
                    <measurement group_id="O5" value="181" spread="185"/>
                    <measurement group_id="O6" value="137" spread="85"/>
                    <measurement group_id="O7" value="70" spread="63"/>
                    <measurement group_id="O8" value="147" spread="73"/>
                    <measurement group_id="O9" value="309" spread="174"/>
                    <measurement group_id="O10" value="-7" spread="9"/>
                    <measurement group_id="O11" value="56" spread="61"/>
                    <measurement group_id="O12" value="59" spread="NA">only 1 participant evaluated</measurement>
                    <measurement group_id="O13" value="-14" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum C3a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12" spread="6"/>
                    <measurement group_id="O2" value="30" spread="42"/>
                    <measurement group_id="O3" value="-22" spread="24"/>
                    <measurement group_id="O4" value="-0" spread="8"/>
                    <measurement group_id="O5" value="71" spread="156"/>
                    <measurement group_id="O6" value="-5" spread="18"/>
                    <measurement group_id="O7" value="14" spread="56"/>
                    <measurement group_id="O8" value="40" spread="50"/>
                    <measurement group_id="O9" value="34" spread="30"/>
                    <measurement group_id="O10" value="-11" spread="23"/>
                    <measurement group_id="O11" value="-18" spread="23"/>
                    <measurement group_id="O12" value="219" spread="NA">only 1 participant evaluated</measurement>
                    <measurement group_id="O13" value="16" spread="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum C4a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5" spread="7"/>
                    <measurement group_id="O2" value="37" spread="70"/>
                    <measurement group_id="O3" value="-11" spread="10"/>
                    <measurement group_id="O4" value="2" spread="8"/>
                    <measurement group_id="O5" value="16" spread="13"/>
                    <measurement group_id="O6" value="-8" spread="27"/>
                    <measurement group_id="O7" value="78" spread="107"/>
                    <measurement group_id="O8" value="60" spread="53"/>
                    <measurement group_id="O9" value="-1" spread="15"/>
                    <measurement group_id="O10" value="-19" spread="35"/>
                    <measurement group_id="O11" value="-35" spread="21"/>
                    <measurement group_id="O12" value="160" spread="NA">only 1 participant evaluated</measurement>
                    <measurement group_id="O13" value="-15" spread="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum C5a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="7"/>
                    <measurement group_id="O2" value="2" spread="7"/>
                    <measurement group_id="O3" value="-16" spread="5"/>
                    <measurement group_id="O4" value="-2" spread="25"/>
                    <measurement group_id="O5" value="-14" spread="7"/>
                    <measurement group_id="O6" value="2" spread="15"/>
                    <measurement group_id="O7" value="0" spread="8"/>
                    <measurement group_id="O8" value="6" spread="6"/>
                    <measurement group_id="O9" value="6" spread="12"/>
                    <measurement group_id="O10" value="-2" spread="18"/>
                    <measurement group_id="O11" value="-4" spread="16"/>
                    <measurement group_id="O12" value="22" spread="NA">only 1 participant evaluated</measurement>
                    <measurement group_id="O13" value="-4" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum CH50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5" spread="8"/>
                    <measurement group_id="O2" value="-14" spread="11"/>
                    <measurement group_id="O3" value="-14" spread="7"/>
                    <measurement group_id="O4" value="-8" spread="8"/>
                    <measurement group_id="O5" value="-16" spread="4"/>
                    <measurement group_id="O6" value="-17" spread="8"/>
                    <measurement group_id="O7" value="-10" spread="4"/>
                    <measurement group_id="O8" value="-13" spread="13"/>
                    <measurement group_id="O9" value="-19" spread="10"/>
                    <measurement group_id="O10" value="-3" spread="9"/>
                    <measurement group_id="O11" value="-3" spread="3"/>
                    <measurement group_id="O12" value="-18" spread="NA">only 1 participant evaluated</measurement>
                    <measurement group_id="O13" value="-0" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day -1 through Day 29 ± 1 day</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Part A: 0.38 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 0.38 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="E2">
          <title>Part A: 1.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="E3">
          <title>Part A: 2.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="E4">
          <title>Part A: 3.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="E5">
          <title>Part A: 4.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="E6">
          <title>Part A: 5.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="E7">
          <title>Part A: 6.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="E8">
          <title>Part A: 7.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="E9">
          <title>Part A: 8.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers</description>
        </group>
        <group group_id="E10">
          <title>Part A: Placebo</title>
          <description>Single dose administration of 0.9% normal saline IV injection in healthy volunteers</description>
        </group>
        <group group_id="E11">
          <title>Part B: 2.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in participants with AATD</description>
        </group>
        <group group_id="E12">
          <title>Part B: 4.0 mg/kg</title>
          <description>Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in participants with AATD</description>
        </group>
        <group group_id="E13">
          <title>Part B: Placebo</title>
          <description>Single dose administration of 0.9% normal saline IV injection in participants with AATD</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rhabdomyolosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral coldness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Operating Officer</name_or_title>
      <organization>Arrowhead Pharmaceuticals, Inc.</organization>
      <phone>6263043400</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

